This discovery gives hope for a more effective and cheaper treatment strategy to millions worldwide suffering from chronic infections
1. A recent discovery by scientists at A*A*STAR’s Singapore Institute for Clinical Sciences (SICS), in close collaboration with researchers at the Singapore Immunology Network (SIgN), provides hope for a new personalised treatment strategy that could use a patient’s own blood to treat the infection. This could help treat millions of people living with chronic infections such as HIV, Hepatitis B or Hepatitis C. These findings were published in the August 2013 issue of The Journal of Clinical Investigation.
2. Patients suffering from chronic infections often have to undergo long periods of anti-viral drug therapy to control the virus. Anti-viral drugs are not fully effective against viruses such as Hepatitis B and Hepatitis C, which have chronically-infected about 400 million worldwide with more than 1,000,000 people dying from Hepatitis-related diseases every year.
3. Vaccines are a potentially effective means to treat chronic viral infections such as this because they can eliminate the virus naturally. However, vaccines for patients with chronic infections are often difficult to produce since these patients already have weak immune responses or the vaccine is not effective due to genetic diversity amongst viruses.
4. The team at SICS led by Prof Antonio Bertoletti has discovered that monocytes, a type of white blood cell that can activate an immune response, are able to capture the virus in chronically-infected patients and use the captured virus to boost the patient’s own immune response.
5. By using the viral antigen already present in the blood of the patient suffering from a chronic illness, this strategy redefines therapeutic vaccines by cutting down on time and resources as there is no need to specially isolate the viral proteins from patients, purify it, and then inactivate it to create a vaccine.
6. All the proteins present within the virus can be used to create a personalised vaccine for each individual. This also means that many of the complex issues associated with current vaccine therapy against chronic infections can be overcome, such as that of genetic diversity of viruses.
7. One of the greatest beneficiaries of this discovery would be chronically-infected patient populations in lower socio-economic strata. By tailoring vaccines to be more specific to each virus and each patient, vaccine production can be simplified and thus less costly. Vaccines produced via this discovery could improve the accessibility of such treatments.
The Latest on: Chronic Infections
- Molecular mechanism of enterovirus infection uncoveredon August 18, 2019 at 11:19 pm
The researchers explain that enteroviruses are one of the commonest infections leading to both acute as well as chronic infections. These are successful viruses that can cause several infectious ...
- Research reveals physiological events leading to successful enterovirus infectionon August 18, 2019 at 10:04 pm
Enteroviruses are one of the most common human pathogens leading to high number of acute and chronic infections worldwide. The physiological events leading to successful enterovirus infection are ...
- Woman suffers chronic UTIs for 45 years, but relief may be closeon August 18, 2019 at 8:06 pm
Chronic UTIs are a major burden on global healthcare, said Schembri, and the problem is magnified by an increase in antibiotic resistance. “Antibiotic treatments can sometimes just stop working on ...
- Fresh basil consumption likely responsible for 205 Cyclospora infections in 11 stateson August 16, 2019 at 9:00 pm
What are the serious and long-term risks of Cyclospora infection? Cyclospora has been associated with a variety of chronic complications such as Guillain-Barre syndrome, reactive arthritis or Reiter’s ...
- Migraine medicine could lead to life-threatening infection; recall announcedon August 16, 2019 at 5:12 pm
For the general population the risks of infection are low, Pfizer said. However, patients with compromised immune systems, cystic fibrosis, and chronic granulomatous disease could suffer from a higher ...
- Migraine medicine recalled, may lead to life-threatening infectionon August 16, 2019 at 10:04 am
However, patients with compromised immune systems, cystic fibrosis and chronic granulomatous disease, may have the potential for serious adverse effects including life-threatening infections. Pfizer ...
- Potentially contaminated migraine medicine may lead to life-threatening infection, FDA issues nationwide recallon August 15, 2019 at 7:50 pm
there is risk of temporary gastrointestinal distress without serious infection. For the general population these risks are low; for certain vulnerable patient populations (such as patients with ...
- Recall announced for migraine medicine that could lead to life-threatening infectionon August 15, 2019 at 7:33 pm
There is also risk of temporary gastrointestinal distress without serious infection. Those with compromised immune systems, cystic fibrosis and chronic granulomatous disease could face serious, ...
- CALQUENCE® (acalabrutinib) Granted US Breakthrough Therapy Designation for Chronic Lymphocytic Leukemiaon August 14, 2019 at 5:00 am
Infections due to hepatitis B virus (HBV ... without obinutuzumab in patients with previously-untreated CLL without 17p deletion or TP53 mutation. Chronic lymphocytic leukemia (CLL) is one of the most ...
- The first chlamydia vaccine could soon be on its way. The common STI can lead to infertility, chronic pain, and an increased risk of HIV.on August 13, 2019 at 9:55 am
There are 1 million new STI cases globally every day, and many current antibiotics used to treat them are becoming antibiotic resistant.
via Google News and Bing News